RESUMO
Two-octyl cyanoacrylate is a popular skin adhesive used for closing surgical incisions. Since Food and Drug Administration approval in 1998, the few reports of adverse reactions following its use have primarily been limited to the nonorthopedic literature. The authors present a case series of contact dermatitis associated with 2-octyl cyanoacrylate following orthopedic surgery and a review of the literature on the diagnosis and treatment of this complication. All 3 patients presented with blistering around their incisions within 2 weeks of surgery and responded to treatment involving removal of the offending agent and use of oral diphenhydramine and hydroxyzine and topical triamcinolone. One case was complicated by a draining hematoma, requiring irrigation and debridement. Complete resolution occurred in all cases. This case series is intended to increase awareness in the orthopedic community of allergic contact dermatitis to 2-octyl cyanoacrylate and its appropriate treatment. [Orthopedics. 2018; 41(2):e289-e291.].
Assuntos
Cianoacrilatos/efeitos adversos , Dermatite de Contato/etiologia , Procedimentos Ortopédicos/efeitos adversos , Adesivos Teciduais/efeitos adversos , Adolescente , Adulto , Criança , Feminino , Hematoma/induzido quimicamente , Humanos , Masculino , Triancinolona/efeitos adversos , Técnicas de Fechamento de Ferimentos/efeitos adversosAssuntos
Queimaduras/complicações , Cicatriz Hipertrófica/radioterapia , Terapia com Luz de Baixa Intensidade/métodos , Missões Médicas/organização & administração , Área Carente de Assistência Médica , Queimaduras/diagnóstico , Cicatriz Hipertrófica/diagnóstico , Saúde Global , Humanos , Escala de Gravidade do Ferimento , Masculino , Pessoa de Meia-Idade , Pobreza , Organização Mundial da Saúde , Ferimentos e Lesões/complicações , Ferimentos e Lesões/diagnósticoRESUMO
BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. RESULTS: The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001). LIMITATIONS: The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. CONCLUSION: Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.